Pharmacokinetics
ADVERSE EVENTS, ADVERSE EVENT, DYSLIPIDEMIA
Pharmacokinetic samples were collected only for HP cohorts.On dosing days (days 1 and 29 (MAD cohorts only)), plasma samples were collected at time 0 (pre-dose), 15 min and 0.5, 1, 2, 3, 6, 9, 12, 18, 24 and 48 h post-dose.The primary objective of the study was to determine the incidence and frequency of adverse events possibly or probably related to treatment as a measure of the safety and tolerability of ARO-ANG3 using escalating single and multiple doses in HPs and multiple doses in patients with dyslipidemia. Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 19.1.